Praxis Precision Medicines, Inc. (PRAX) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST
Company Participants
Marcio Souza – President, CEO & Director
Conference Call Participants
Lin Tsai – Jefferies LLC, Research Division
Presentation
Lin Tsai
Jefferies LLC, Research Division
All right. We’re going to get started with our next session. I’m Andrew Tsai, Senior Biotech Analyst at Jefferies. And it’s my pleasure to have Marcio Souza, joining me today, CEO of Praxis. Welcome, Marcio.
Marcio Souza
President, CEO & Director
Thank you. Thanks, Andrew. Appreciate it.
Question-and-Answer Session
Lin Tsai
Jefferies LLC, Research Division
Maybe really briefly because we do want to — I do want to tackle a lot of things. Maybe walk through the — what you’re working on in the pipeline and milestones we can expect over the next 6 to 12 months, that would be helpful to start.
Marcio Souza
President, CEO & Director
Absolutely, and it’s always a pleasure to be here. Like there is always a lot. I feel every time we talk that there’s a lot going on with the company, and we’re very pleased and happy with that, but it still remain quite humble on the heels of a very successful essential tremor readout on both studies. So we have that filing coming up, hopefully early in the year, by early in the year. A number of epilepsy assets progressing, including our DEE program with relutrigine. First for a rare indication or 2 rare indications for SCN2A and 8A. Those are coming up. The interim analysis, we’re doing that study kind of right now. And by right now, I mean in Q4. We’ll continue to recruit quite nicely, may I say, on the larger study, which we call EMERALD, which should read out next year. And in between, assuming that the interim is going to be positive here, of course, would be filing an NDA for that indication. So the next — if I restrict to the
